For all press inquiries, please email theteam@rxtrospect.com

Newsroom

Email

Get notified of key updates and new features

Join hundreds of others who get insights on what’s happening across the United States and European landscapes, with details that cover recent approvals in oncology, and much more.

WHAT’S happening AT RxTROSPECT

2025 Product updates

██████ Done Oncology approvals in United States

██████ Done Oncology approvals in Europe

███░░ 2025 release ➜ Cell & Gene Therapy approvals

███░░ Coming soon ➜ Neurology approvals

███░░ Coming soon ➜ Virology approvals

███░░ Coming soon ➜ Cardiology approvals

███░░ Coming soon ➜ Endocrinology approvals

███░░ Coming soon ➜ Rare Disease & Orphan Drug approvals

██████ Done Oncology approvals in United States

██████ Done Oncology approvals in Europe

███░░ 2025 release ➜ Cell & Gene Therapy approvals

███░░ Coming soon ➜ Neurology approvals

███░░ Coming soon ➜ Virology approvals

███░░ Coming soon ➜ Cardiology approvals

███░░ Coming soon ➜ Endocrinology approvals

███░░ Coming soon ➜ Rare Disease & Orphan Drug approvals

Press & regulatory approvals

Featured
ENHERTU® Approved in the U.S. as First HER2 Directed Therapy for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following Disease Progression After One or More Endocrine Therapies
FDA approves sotorasib with panitumumab for KRAS G12C-mutated colorectal cancer
FDA approves datopotamab deruxtecan-dlnk for unresectable or metastatic, HR-positive, HER2-negative breast cancer
FDA approves acalabrutinib with bendamustine and rituximab for previously untreated MCL
BMS Receives EU Approval for nivo+ipi plus for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer
FDA approves OPDIVO Subcutaneous
TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy
FDA grants accelerated approval to encorafenib with cetuximab and mFOLFOX6 for metastatic colorectal cancer with a BRAF V600E mutation
FDA approves ensartinib for ALK-positive locally advanced or metastatic non-small cell lung cancer
FDA approves Unloxcyt, a new PD-L1 from Checkpoint Therapeutics, Inc.

Search for all our news and updates

Media kit

✔ Brand guidelines

✔ RxTROSPECT logo

✔ Leadership photos

✔ Product images